General Information of Drug (ID: DM581CS)

Drug Name
CD19 and CD22 CAR-T Cells Drug Info
Indication
Disease Entry ICD 11 Status REF
B-cell lymphoma 2A86 Phase 1/2 [1]
leukaemia 2A60-2B33 Phase 1/2 [1]
Lymphoma 2A80-2A86 Phase 1/2 [2]
Cross-matching ID
TTD Drug ID
DM581CS

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug(s) Targeting B-cell receptor CD22 (CD22)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Moxetumomab pasudotox DMN63DZ Hairy cell leukaemia 2A82.2 Approved [3]
Inotuzumab ozogamicin DMAC130 Acute lymphoblastic leukaemia 2A85 Approved [4]
OspA lipoprotein DMF5ZB3 Lyme disease 1C1G Approved [5]
Epratuzumab DMI1ZXV Acute lymphoblastic leukaemia 2A85 Phase 3 [6]
CAR-T cells targeting CD22 DM6XN4C Non-hodgkin lymphoma 2B33.5 Phase 2 [7]
BL-22 DM8R71T Acute lymphoblastic leukaemia 2A85 Phase 2 [8]
CAR-T cells targeting CD22 DM6XN4C Non-hodgkin lymphoma 2B33.5 Phase 2 [9]
AUTO3 DMC5NSO Acute lymphoblastic leukaemia 2A85 Phase 1/2 [10]
CART-19/22 DMX0R1E leukaemia 2A60-2B33 Phase 1/2 [11]
4SCAR19/22 T cells DMI8TW3 B-cell lymphoma 2A86 Phase 1/2 [12]
Moxetumomab pasudotox DMN63DZ Hairy cell leukaemia 2A82.2 Approved [3]
Inotuzumab ozogamicin DMAC130 Acute lymphoblastic leukaemia 2A85 Approved [4]
OspA lipoprotein DMF5ZB3 Lyme disease 1C1G Approved [5]
Epratuzumab DMI1ZXV Acute lymphoblastic leukaemia 2A85 Phase 3 [6]
CAR-T cells targeting CD22 DM6XN4C Non-hodgkin lymphoma 2B33.5 Phase 2 [7]
BL-22 DM8R71T Acute lymphoblastic leukaemia 2A85 Phase 2 [8]
CAR-T cells targeting CD22 DM6XN4C Non-hodgkin lymphoma 2B33.5 Phase 2 [9]
AUTO3 DMC5NSO Acute lymphoblastic leukaemia 2A85 Phase 1/2 [10]
CART-19/22 DMX0R1E leukaemia 2A60-2B33 Phase 1/2 [11]
4SCAR19/22 T cells DMI8TW3 B-cell lymphoma 2A86 Phase 1/2 [12]
⏷ Show the Full List of 20 Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [13]
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [14]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [15]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [16]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [17]
Tecartus DMYQCWT Mantle cell lymphoma 2A85.5 Approved [18]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [19]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [20]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [21]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [22]
Tisagenlecleucel DMM9BJD Acute lymphoblastic leukaemia 2A85 Approved [13]
Blinatumomab DMGECIJ Acute lymphoblastic leukaemia 2A85 Approved [14]
Axicabtagene ciloleucel DMYHN59 Diffuse large B-cell lymphoma 2A81 Approved [15]
Lisocabtagene maraleucel DMP45ME Large B-cell lymphoma 2A81 Approved [16]
Inebilizumab DMI0RHA Neuromyelitis optica spectrum disorder 8E4A.0 Approved [17]
Tecartus DMYQCWT Mantle cell lymphoma 2A85.5 Approved [18]
Loncastuximab tesirine DMXSVGI Diffuse large B-cell lymphoma 2A81 Approved [19]
Obexelimab DMVIC4J IgG4 related disease 4A43.0 Phase 3 [20]
MOR-208 DMDQOWT Diffuse large B-cell lymphoma 2A81 Phase 2/3 [21]
CART-19 DMST3FM Acute lymphoblastic leukaemia 2A85 Phase 2/3 [22]
⏷ Show the Full List of 20 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B-cell receptor CD22 (CD22) TTM6QSK CD22_HUMAN CAR-T-Cell-Therapy(Dual specific) [2]
B-lymphocyte surface antigen B4 (CD19) TTW640A CD19_HUMAN CAR-T-Cell-Therapy(Dual specific) [2]

References

1 ClinicalTrials.gov (NCT03398967) A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma
2 ClinicalTrials.gov (NCT03468153) Dual Specificity CD19 and CD22 CAR-T Cell Immunotherapy for CD19+CD22+ Relapsed and Refractory Lymphoma
3 Antibody fusion proteins: anti-CD22 recombinant immunotoxin moxetumomab pasudotox. Clin Cancer Res. 2011 Oct 15;17(20):6398-405.
4 Results of inotuzumab ozogamicin, a CD22 monoclonal antibody, in refractory and relapsed acute lymphocytic leukemia. Cancer. 2013 Aug 1;119(15):2728-36.
5 Safety and immunogenicity of recombinant Bacille Calmette-Gu |rin (rBCG) expressing Borrelia burgdorferi outer surface protein A (OspA) lipoprotein in adult volunteers: a candidate Lyme disease vaccine. Vaccine. 1999 Feb 26;17(7-8):904-14.
6 New developments in immunosuppressive therapy for heart transplantation. Expert Opin Emerg Drugs. 2009 Mar;14(1):1-21.
7 ClinicalTrials.gov (NCT03196830) CAR-T for R/R B-NHL
8 Anti-CD22 immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-positive hematologic malignancies of childhood: preclinical studies and phase I clinical trial. Clin Cancer Res. 2010 Mar 15;16(6):1894-903.
9 ClinicalTrials.gov (NCT03312205) CAR-T Cells for Relapsed or Refractory Haematopoietic and Lymphoid Malignancies
10 ClinicalTrials.gov (NCT03289455) CD19 /22 CAR T Cells (AUTO3) for the Treatment of B Cell ALL
11 ClinicalTrials.gov (NCT03614858) CD19/CD22-targeted Chimeric Antigen Receptor Engineered T Cell (CART) in B-Cell Acute Lymphoblastic Leukemia.
12 ClinicalTrials.gov (NCT03098355) Interleukin-2 Following 4SCAR19/22 T Cells Targeting Refractory and/or Recurrent B Cell Malignancies
13 2017 FDA drug approvals.Nat Rev Drug Discov. 2018 Feb;17(2):81-85.
14 2014 FDA drug approvals. Nat Rev Drug Discov. 2015 Feb;14(2):77-81.
15 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services
16 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
17 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services. 2020
18 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health Human Services.
19 Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma. Blood. 2021 May 13;137(19):2634-2645.
20 Emerging B-Cell Therapies in Systemic Lupus Erythematosus. Ther Clin Risk Manag. 2021 Jan 14;17:39-54.
21 A phase 1 trial of the Fc-engineered CD19 antibody XmAb5574 (MOR00208) demonstrates safety and preliminary efficacy in relapsed CLL. Blood. 2014 Dec 4;124(24):3553-60.
22 ClinicalTrials.gov (NCT03027739) CART-19 Cells For MRD Positive CD19+ ALL